← Leaderboards
David Reardon
Duke University
$8,732,934
Attributed
$8,732,934
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,884,093 · 7
By mechanism
P01$16,876,429 · 2
P50$5,371,145 · 3
R21$636,519 · 1
P20$0 · 1
Top collaborators
- E. Antonio Chiocca5 shared
Most similar at Duke University
Same institution · by research overlap
- Darell D Bigner$25,397,506
- John H Sampson$43,413,436
- Henry S. Friedman$12,588,060
- Matthias Gromeier$11,871,021
- Smita K Nair$1,645,249
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTumorCollaborationsSafetyImmunotherapyGlioblastomaVaccinesResponseMalignant NeoplasmsInnovationRadiation TherapyBrain NeoplasmsDesignPre-ClinicalMalignant Neoplasm Of BrainNewly DiagnosedResearch PersonnelSamplingOperative Surgical ProceduresQuality Of LifeEffector T CellImmunosuppressionAnti-Pd-1Immunoregulation
Grant awards (28)
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,680,832
P01 · FY2024 · CA
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy$503,520
P01 · FY2024 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,810,976
P01 · FY2023 · CA
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy$564,907
P01 · FY2023 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,801,934
P01 · FY2022 · CA
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy$555,865
P01 · FY2022 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,832,522
P01 · FY2021 · CA
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy$540,614
P01 · FY2021 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$3,024,895
P01 · FY2020 · CA
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy$560,364
P01 · FY2020 · CA · contact PI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS$491,231
P50 · FY2013 · NS · contact PI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS$513,111
P50 · FY2012 · NS · contact PI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS$504,772
P50 · FY2011 · NS · contact PI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS$543,088
P50 · FY2010 · NS · contact PI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS$454,899
P50 · FY2009 · NS · contact PI
Translational Clinical Trials in Neuro-Oncology$372,342
P50 · FY2008 · NS · contact PI
CORE--PHASE I/II CLINICAL TRIALS$272,925
P50 · FY2008 · CA · contact PI
Translational Clinical Trials in Neuro-Oncology$383,501
P50 · FY2007 · NS · contact PI
CORE--PHASE I/II CLINICAL TRIALS$286,803
P50 · FY2007 · CA · contact PI
Translational Clinical Trials in Neuro-Oncology$344,416
P50 · FY2006 · NS · contact PI
CORE-3-PHASE I/II CLINICAL TRIALS$171,681
P50 · FY2006 · CA · contact PI
Translational Clinical Trials in Neuro-Oncology$344,416
P50 · FY2005 · NS
CORE-3-PHASE I/II CLINICAL TRIALS$171,686
P50 · FY2005 · CA
Translational Clinical Trials in Neuro-Oncology$344,416
P50 · FY2004 · NS
Phase II Study of 44Gy from 131I-81C6 for CNS Tumors$317,899
R21 · FY2004 · CA
CORE-3-PHASE I/II CLINICAL TRIALS$171,858
P50 · FY2004 · CA
Phase II Study of 44Gy from 131I-81C6 for CNS Tumors$318,620
R21 · FY2003 · CA
CORE--PHASE I / II CLINICAL TRIALS CORE$0
P20 · FY2002 · CA